心力衰竭中的多药丸:简化治疗的途径和改善的坚持和结果
Kalliopi Keramida1, Gianluigi Savarese2, Gerasimos Filippatos3
1Cardiology Department, General Anti-Cancer, Oncological Hospital, Agios Savvas, Athens, Greece.
Heart failure reviews
|September 5, 2025
概括
通过结合必要的药物来简化心力衰竭 (HF) 治疗,旨在改善患者的治疗效果. 需要进一步的研究来证实其在不同HF群体中的有效性和安全性.
科学领域:
- 心血管医学
- 药理学
- 医疗服务研究
背景情况:
- 心脏衰竭对全球健康和经济造成重大负担.
- 在HF治疗中,对指导药物治疗 (GDMT) 的不充分遵守是一个主要的挑战,多药和复杂的治疗方案加剧了这一问题.
- 现有的高血压治疗常常涉及多种药物,导致患者坚持治疗的挑战.
研究的目的:
- 探索多药丸治疗作为简化高血压治疗的实用策略的潜力.
- 为了提高患者对必要的HF药物的坚持.
- 通过简化药物治疗方案,改善心力衰竭患者的临床结果.
主要方法:
- 对心血管疾病中的多药药策略的现有文献的综述.
- 建议对HF多药剂治疗进行两种实施方法:早期低剂量启动和转换稳定患者.
- 对不同HF表型和正在进行的临床试验量身定制的配方进行讨论.
主要成果:
- 多种药丸方法提供了潜在的好处,包括改善HF患者的坚持,负担能力和简化护理.
- 在其他心血管疾病中成功应用表明HF的可行性.
- 目前正在进行的试验正在评估多药治疗的疗效和安全性.
结论:
- 多种药丸治疗是一个有前途的策略, 简化HF的管理和改善坚持.
- 关键因素包括最佳的药物选择,药物相互作用的管理,灵活的剂量和患者特异性因素.
- 进一步实践的临床试验对于在不同HF群体中验证疗效,安全性和可行性至关重要.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505


